Composition for preventing or improving peripheral neuropathy

Abstract

Compositions which contain an amino acid containing serine and a lipid containing a n-3 fatty acid are useful for the prophylaxis or improvement of peripheral neuropathy.

1 . A composition for the prophylaxis or improvement of peripheral neuropathy, which comprises at least one amino acid comprising serine, and at least one lipid comprising at least one n-3 fatty acid. 
     
     
         2 . The composition according to  claim 1 , wherein said at least one n-3 fatty acid comprises one or more kinds selected from the group consisting of eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid. 
     
     
         3 . The composition according to  claim 1 , wherein said serine is present in an amount of not less than 50 wt % relative to the total amount of amino acid. 
     
     
         4 . The composition according to  claim 1 , which (1) is substantially free of threonine, or (2) has a weight ratio of serine relative to threonine of not less than 2.60. 
     
     
         5 . The composition according to  claim 1 , wherein the amount of said at least one n-3 fatty acid is not less than 20 wt % relative to the total amount of said at least one lipid. 
     
     
         6 . The composition according to  claim 1 , which is in a unit package form for single intake, and comprises not less than 0.1 g of serine in one unit and not less than 0.03 g of n-3 fatty acid in one unit. 
     
     
         7 . The composition according to  claim 1 , which is a medicament. 
     
     
         8 . A method for the prophylaxis or improvement of peripheral neuropathy, comprising administering to a subject in need thereof an effective amount of a composition comprising at least one amino acid comprising serine, and at least one lipid comprising at least one n-3 fatty acid. 
     
     
         9 . The method according to  claim 8 , wherein said at least one n-3 fatty acid comprises one or more kinds selected from the group consisting of eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid. 
     
     
         10 . The method according to  claim 8 , wherein said serine is present in said composition in an amount of not less than 50 wt % relative to the total amount of amino acid in said composition. 
     
     
         11 . The method according to  claim 8 , wherein said composition: (1) is substantially free of threonine; or (2) has a weight ratio of serine relative to threonine of not less than 2.60. 
     
     
         12 . The method according to  claim 8 , wherein the amount of said at least one n-3 fatty acid insaid composition is not less than 20 wt % relative to the total amount of said at least one lipid in said composition. 
     
     
         13 . The method according to  claim 8 , wherein said composition is administered in a unit package form for single intake, and comprises not less than 0.1 g of serine in one unit and not less than 0.03 g of n-3 fatty acid in one unit. 
     
     
         14 . The method according to  claim 8 , wherein said peripheral neuropathy is one or more selected from the group consisting of peripheral neuropathy due to an anticancer agent, peripheral neuropathy due to knee osteoarthritis, backbone neuropathy, peripheral neuropathy due to mechanical compression of peripheral nerve trunk, diabetic peripheral neuropathy, renal disease uremic peripheral neuropathy, peripheral neuropathy due to herpes roster, and Guillain-Barre syndrome. 
     
     
         15 . The method according to  claim 8 , wherein said peripheral neuropathy is peripheral neuropathy due to an anticancer agent or peripheral neuropathy due to knee osteoarthritis. 
     
     
         16 . A method for the prophylaxis or improvement of activity decline due to peripheral neuropathy, comprising administering to a subject in need thereof an effective amount of a composition comprising at least one amine acid comprising serine, and at least one lipid comprising at least one n-3 fatty acid. 
     
     
         17 . The method according to  claim 16 , wherein said at least one n-3 fatty acid comprises one or more kinds selected from the group consisting of eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid. 
     
     
         16 . The method according to  claim 16 , wherein said serine is present in said composition in an amount of not less than 50 wt % relative to the total amount of amino acid in said composition. 
     
     
         19 . The method according to  claim 16 , wherein said composition: (1) is substantially free of threonine; or (2) has a weight ratio of serine relative to threonine of not less than 2.60. 
     
     
         20 . The method according to  claim 16 , wherein the amount of said at least one n-3 fatty acid insaid composition is not less than 20 wt % relative to the total amount of said at least one lipid in said composition. 
     
     
         21 . The method according to  claim 16 , wherein said composition is administered in a unit package form for single intake, and comprises not less than 0.1 g of serine in one unit and not less than 0.03 g of n-3 fatty acid in one unit. 
     
     
         22 . The method according to  claim 16 , wherein said peripheral neuropathy is one or more selected from the group consisting of peripheral neuropathy due to an anticancer agent, peripheral neuropathy due to knee osteoarthritis, backbone neuropathy, peripheral neuropathy due to mechanical compression of peripheral nerve trunk, diabetic peripheral neuropathy, renal disease uremic peripheral neuropathy, peripheral neuropathy due to herpes zoster, and Guillain-Barre syndrome. 
     
     
         23 . The method according to  claim 16 , wherein said peripheral neuropathy is peripheral neuropathy due to on anticancer agent or peripheral neuropathy due to knee osteoarthritis.